Should I Buy MBOT? MBOT 2026 Analysis

Should You Buy Microbot Medical Inc (MBOT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.760

1 Day change

8.64%

52 Week Range

4.670

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient investor: the stock is in a strong downtrend (bearish MAs + weakening MACD), so the path of least resistance remains lower despite being oversold.
Oversold RSI (~16.9) can produce a dead-cat bounce, but without a confirming reversal signal (and no Intellectia buy signals), the risk of catching a falling knife is high.
Near-term event risk is elevated with QDEC 2025 earnings on 2026-02-11 (pre-market), which can move a small-cap materially in either direction.
Options sentiment is very bullish (extremely low put/call ratios), but implied volatility is extremely high (IV percentile ~91%), implying the market expects large moves and pricing in risk.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend: Bearish trend structure with SMA_200 > SMA_20 > SMA_5 (classic downtrend alignment).
Momentum: MACD histogram is negative (-0.0257) and negatively expanding, signaling downside momentum is still strengthening.
Mean-reversion setup: RSI_6 at 16.866 indicates deeply oversold conditions; bounce potential exists, but it is not the same as a confirmed trend reversal.
Key levels:
- Price: 1.695
- Resistance/Pivot area: Pivot 1.861, then R1 2.004 (regaining/holding above pivot would be an early improvement).
- Support: S1 1.717 (already below), S2 1.628 (next meaningful downside level).
Broad tape: S&P 500 down ~1.17% today, which is a headwind for risk-on small caps.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Extremely low put/call ratios (OI PCR 0.08; Volume PCR 0.16) suggest strongly bullish skew (more calls than puts).
Volatility: 30D IV ~172.62% with IV percentile ~91.24% (options are very expensive; market is pricing big moves).
Activity: Today’s option volume 323, which is ~55% of 30-day average (not a fresh volume surge).
Open interest: Calls OI 33,662 vs puts OI 2,556; total OI 36,218—call-heavy structure supports bullish sentiment but does not override the bearish price trend.

Technical Summary

Sell

Buy

Positive Catalysts

- Product/commercial momentum: LIBERTY® Endovascular Robotic System is being showcased at a major clinical meeting, supporting awareness during limited market release.
- Differentiation: Company highlights LIBERTY as the only FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures.
- Upcoming commercialization milestone: Full market release targeted around April 2026 (conference-driven launch/visibility catalyst).
- Analyst support: Roth initiated with a Buy and $5.50 PT, explicitly citing FDA clearance and early commercial use.

Neutral/Negative Catalysts

- Technical damage: Strong downtrend with weakening momentum (bearish MAs + negative, expanding MACD) increases probability that rallies get sold.
- Earnings catalyst risk: QDEC 2025 earnings on 2026-02-11 (pre-market) can trigger sharp downside if cash burn/updates disappoint.
- Fundamentals still early-stage: Last reported quarter shows no revenue (still pre-scale commercialization).
- High implied volatility: Indicates the market expects large moves; downside gaps are plausible in small-cap biotech/med-tech names.

Financial Performance

Latest provided quarter: 2025/Q3.
Revenue: 0 (no growth base; commercialization still emerging).
Net income: -$3.577M, improved ~11.26% YoY (loss narrowed), but still meaningfully negative.
EPS: -$0.07, down ~65% YoY (worse per-share loss despite net loss improvement—likely share count/other effects).
Gross margin: 0 (consistent with no reported revenue).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst action: (2025-12-03) Roth Capital (Kyle Bauser) initiated coverage with Buy and $5.50 price target.
Rationale cited: FDA clearance (Sep), early commercial use in select U.S. hospitals, and expected broader release (April 2026).
Wall Street pros view:
- Pros: Clear regulatory milestone + robotics differentiation + commercialization timeline could re-rate the stock if adoption ramps.
- Cons: Execution risk remains high (early commercialization, limited financial traction so far), and current chart/price action contradicts the bullish thesis near-term.
Institutional/insider trend: Hedge funds neutral (no notable last-quarter trend); insiders neutral (no notable last-month trend).
Politicians/Congress: No recent congress trading data available in the last 90 days.

2 Analyst Rating

Wall Street analysts forecast MBOT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBOT is 8.75 USD with a low forecast of 5.5 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.620

Low

5.5

Averages

8.75

High

Current: 1.620

Low

5.5

Averages

8.75

High

Roth Capital

Kyle Bauser

Buy

initiated

$5.50

AI Analysis

2025-12-03

Reason

Roth Capital

Kyle Bauser

Price Target

$5.50

AI Analysis

2025-12-03

initiated

Buy

Reason

Roth Capital analyst Kyle Bauser initiated coverage of Microbot Medical with a Buy rating and $5.50 price target. The firm says the company's Liberty Endovascular Robotic System achieved FDA clearance in September and has begun commercial use in select U.S. hospitals ahead of a full market release in April 2026. Roth thinks the technology will be useful within procedures that require navigation of complex vascular anatomy while also reducing physical strain and radiation exposure.

H.C. Wainwright

Raghuram Selvaraju

Buy

maintain

$9 -> $12

2025-09-11

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$9 -> $12

2025-09-11

maintain

Buy

Reason

H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Microbot Medical to $12 from $9 and keeps a Buy rating on the shares after the FDA granted 510(k) clearance for the company's Liberty System. This is the first FDA-approved, single-use, remotely operated robotic system for peripheral endovascular procedures, the analyst tells investors in a research note. The firm says the initial addressable market comprises 2.5M peripheral endovascular procedures annually in the U.S.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MBOT

Unlock Now

MBOT Should I Buy

MBOT Should I Buy

Should You Buy Microbot Medical Inc (MBOT) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch